Gene Therapy Clinical Trials
Phase I Compare OS in Post-CyberKnife Radiosurgery Tx in 1-3 VS 4 or More Brain Metastases
The investigators will learn from this study if the CyberKnife radiosurgery (CK RS) treatment of patients with 1-3 versus 4 or more brain metastases results in the same overall survivals. The importance of this new knowledge will be to determine the treatment efficacy of CK RS with 1-3 versus 4 or more brain metastases. The outcome of this trial would give data to support either the continuation or modification of the CK RS treatment of patients with brain metastases.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Eligibility
Inclusion Criteria:
1. the presence of a tumor metastasis or tumor metastases to the brain as manifested by
the neurological examination and visibility of the metastatic lesion(s) on MRI and CT
scans
2. a Karnofsky performance status (KPS) score of greater than or equal to 60.
Exclusion Criteria:
The exclusion criteria are the converse of the above, i.e. patients without a brain tumor
metastasis or brain tumor metastases or a KPS of less than 60.
Ages Eligible for Study
21 Years - 95 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Steven Chang
650-723-5573
Not Recruiting